MET and non-small cell lung carcinoma: Though MET mutation-specific results are not yet reported, the 40% ORR towards EGFR exon 20 insertions led to the amivantamab FDA approval for EGFR exon 20 insertions in NSCLC patients after platinum chemotherapy progression [169].